The Effects of Apigenin in the Treatment of Diabetic Nephropathy : A Systematic Review of Non-clinical Studies
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
PURPOSE: Diabetes is one of the important and growing diseases in the world. Among the most common diabetic complications are renal adverse effects. The use of apigenin may prevent the development and progression of diabetes-related injuries. The current study aims to review the effects of apigenin in the treatment of diabetic nephropathy.
METHODS: In this review, a systematic search was performed based on PRISMA guidelines for obtaining all relevant studies on "the effects of apigenin against diabetic nephropathy" in various electronic databases up to September 2022. Ninety-one articles were obtained and screened in accordance with the predefined inclusion and exclusion criteria. Seven eligible articles were finally included in this review.
RESULTS: The experimental findings revealed that hyperglycemia led to the decreased cell viability of kidney cells and body weight loss and an increased kidney weight of rats; however, apigenin administration had a reverse effect on these evaluated parameters. It was also found that hyperglycemia could induce alterations in the biochemical and renal function-related parameters as well as histopathological injuries in kidney cells or tissue; in contrast, the apigenin administration could ameliorate the hyperglycemia-induced renal adverse effects.
CONCLUSION: The results indicated that the use of apigenin could mitigate diabetes-induced renal adverse effects, mainly through its antioxidant, anti-apoptotic, and anti-inflammatory activities. Since the findings of this study are based on experimental studies, suggesting the use of apigenin (as a nephroprotective agent) against diabetic nephropathy requires further clinical studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - 24(2024), 3 vom: 17., Seite 341-354 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muhammed, Thikra Majid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7V515PI7F6 |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 30.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389557523666230811092423 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367728559 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367728559 | ||
| 003 | DE-627 | ||
| 005 | 20240130232212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389557523666230811092423 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM367728559 | ||
| 035 | |a (NLM)38282447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muhammed, Thikra Majid |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effects of Apigenin in the Treatment of Diabetic Nephropathy |b A Systematic Review of Non-clinical Studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a PURPOSE: Diabetes is one of the important and growing diseases in the world. Among the most common diabetic complications are renal adverse effects. The use of apigenin may prevent the development and progression of diabetes-related injuries. The current study aims to review the effects of apigenin in the treatment of diabetic nephropathy | ||
| 520 | |a METHODS: In this review, a systematic search was performed based on PRISMA guidelines for obtaining all relevant studies on "the effects of apigenin against diabetic nephropathy" in various electronic databases up to September 2022. Ninety-one articles were obtained and screened in accordance with the predefined inclusion and exclusion criteria. Seven eligible articles were finally included in this review | ||
| 520 | |a RESULTS: The experimental findings revealed that hyperglycemia led to the decreased cell viability of kidney cells and body weight loss and an increased kidney weight of rats; however, apigenin administration had a reverse effect on these evaluated parameters. It was also found that hyperglycemia could induce alterations in the biochemical and renal function-related parameters as well as histopathological injuries in kidney cells or tissue; in contrast, the apigenin administration could ameliorate the hyperglycemia-induced renal adverse effects | ||
| 520 | |a CONCLUSION: The results indicated that the use of apigenin could mitigate diabetes-induced renal adverse effects, mainly through its antioxidant, anti-apoptotic, and anti-inflammatory activities. Since the findings of this study are based on experimental studies, suggesting the use of apigenin (as a nephroprotective agent) against diabetic nephropathy requires further clinical studies | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apigenin | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a nephropathy | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a systematic review. | |
| 650 | 7 | |a Apigenin |2 NLM | |
| 650 | 7 | |a 7V515PI7F6 |2 NLM | |
| 700 | 1 | |a Jalil, Abduladheem Turki |e verfasserin |4 aut | |
| 700 | 1 | |a Taher, Waam Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Aminov, Zafar |e verfasserin |4 aut | |
| 700 | 1 | |a Alsaikhan, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Coronel, Andrés Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Ramaiah, Pushpamala |e verfasserin |4 aut | |
| 700 | 1 | |a Farhood, Bagher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g 24(2024), 3 vom: 17., Seite 341-354 |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:3 |g day:17 |g pages:341-354 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389557523666230811092423 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 3 |b 17 |h 341-354 | ||